Search - tctmd.com

Displaying 21 - 40 of 2992

Sort: Relevancy | Date

Presentation TCT 2025

TCT 563: Comparative Outcomes of Mavacamten with AV Nodal Blockers vs. AV Nodal Blockers Alone in Patients with Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

Presenter: Aditya Desai

October 28, 2025

Presentation TCT 2025

Stent Failure Through the Ages: BMS, First-Generation DES, and Beyond

Presenter: Gary S. Mintz

October 28, 2025

Presentation TCT 2025

TCT 108: Intracoronary Imaging Values As Alternative Approach to Evaluate Significant Ischemia at Proximal Left Descending Artery

Presenter: Satoshi Terashima

October 28, 2025

Presentation TCT 2025

Should Sham Control vs Open Trial Design Make a Difference for Device Regulators and Guideline Makers?

Presenter: Gregg W. Stone

October 28, 2025

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Conference News TCT 2025

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

Caitlin E. Cox

October 27, 2025

Presentation TCT 2025

The SmartWave Lithotripsy System for Valvular Heart Disease Treatment: Technology Description and Early Clinical Results

Presenter: Kent Chak-yu So

October 27, 2025

Presentation TCT 2025

The DragonFly T-TEER for Tricuspid Regurgitation: Technology Description and Clinical Results (Case in a Box)

Presenter: Jian'an Wang

October 27, 2025

Presentation TCT 2025

TCT 945: The TASMAN Study: Third (3G) Alongside Second (2G) Generation Drug Eluting Stent (DES) and overall MACCE At Nepean: Insights from a large west of Sydney Tertiary centre during the Transition from 2G to 3G DES.

Presenter: Robert T. Gerber

October 27, 2025

Presentation TCT 2025

TCT 288: The Diabetes Effect: Mortality Risk Persists in Cardiogenic Shock STEMI Despite Contemporary PCI

Presenter: Miles Chapman

October 27, 2025

Presentation TCT 2025

Can Adaptive and Single-Arm Studies Meet the Needs of Key Stakeholders?

Presenter: Rasha Al-Lamee

October 27, 2025

Presentation TCT 2025

TCT 289: Age >65 in STEMI Cardiogenic Shock: Persistent Mortality Risk Despite PCI in a System Without Surgical or Mechanical Escalation

Presenter: Miles Chapman

October 27, 2025

Presentation TCT 2025

Case-Based Discussion: Designing a Contemporary Cardiovascular Trial

Presenter: Stephan Windecker

October 27, 2025

Presentation TCT 2025

Modifying the Win Ratio for Noninferiority Trials: A Bridge Too Far?

Presenter: Björn Redfors

October 27, 2025

Presentation TCT 2025

Is the WIN ratio always a “Winner”: Where It’s Useful, Where It’s Not

Presenter: John Gregson

October 27, 2025

Presentation TCT 2025

Adaptive and Sequential Designs: From Concept to Execution

Presenter: Graeme L. Hickey

October 27, 2025

Presentation TCT 2025

Smarter Trial Design: Using AI and Real-World Data for Protocol Modeling and Trial Feasibility

Presenter: Harun Kundi

October 27, 2025

Presentation TCT 2025

Siegel THV: Unique Design Features

Presenter: Pradeep K. Yadav

October 27, 2025

Presentation TCT 2025

Navitor Vision Valve Design

Presenter: Deepak R. Talreja

October 27, 2025

Presentation TCT 2025

Non-Inferiority Trials – Bridge or Barrier to Patient-Centered Progress?

Presenter: Sanjay Kaul

October 27, 2025

Advertisement

TCT 563: Comparative Outcomes of Mavacamten with AV Nodal Blockers vs. AV Nodal Blockers Alone in Patients with Hypertrophic Obstructive Cardiomyopathy: A Retrospective Cohort Study

Stent Failure Through the Ages: BMS, First-Generation DES, and Beyond

TCT 108: Intracoronary Imaging Values As Alternative Approach to Evaluate Significant Ischemia at Proximal Left Descending Artery

Should Sham Control vs Open Trial Design Make a Difference for Device Regulators and Guideline Makers?

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

PREVUE-VALVE Charts the Prevalence of Valve Disease in the United States

The SmartWave Lithotripsy System for Valvular Heart Disease Treatment: Technology Description and Early Clinical Results

The DragonFly T-TEER for Tricuspid Regurgitation: Technology Description and Clinical Results (Case in a Box)

TCT 945: The TASMAN Study: Third (3G) Alongside Second (2G) Generation Drug Eluting Stent (DES) and overall MACCE At Nepean: Insights from a large west of Sydney Tertiary centre during the Transition from 2G to 3G DES.

TCT 288: The Diabetes Effect: Mortality Risk Persists in Cardiogenic Shock STEMI Despite Contemporary PCI

Can Adaptive and Single-Arm Studies Meet the Needs of Key Stakeholders?

TCT 289: Age >65 in STEMI Cardiogenic Shock: Persistent Mortality Risk Despite PCI in a System Without Surgical or Mechanical Escalation

Case-Based Discussion: Designing a Contemporary Cardiovascular Trial

Modifying the Win Ratio for Noninferiority Trials: A Bridge Too Far?

Is the WIN ratio always a “Winner”: Where It’s Useful, Where It’s Not

Adaptive and Sequential Designs: From Concept to Execution

Smarter Trial Design: Using AI and Real-World Data for Protocol Modeling and Trial Feasibility

Siegel THV: Unique Design Features

Navitor Vision Valve Design

Non-Inferiority Trials – Bridge or Barrier to Patient-Centered Progress?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content